Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Generics Could Come 15 Months Earlier Than Anticipated After Patent Deemed Invalid

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer says “technical defect” in patent could be corrected with U.S. Patent and Trademark Office.
Advertisement

Related Content

Pfizer Wins Lipitor Reversal
Pfizer Wins Lipitor Reversal
Pfizer Terminates Torcetrapib Program
Pfizer Terminates Torcetrapib Program
Lipitor’s U.K. Exclusivity Affirmed In Appellate Decision
Pfizer Could Expect Major Lipitor Sales Decline By 2007, Report Says
Pfizer Lipitor Patents Valid, Infringed By Ranbaxy, Court Says
Pfizer Lipitor Patents Valid, Infringed By Ranbaxy, Court Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS064706

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel